Novel therapies for metastatic prostate cancer

ABSTRACT

Introduction

Patients with metastatic prostate cancer, especially in the castrate-resistant setting, have a poor prognosis. Many agents have been approved for metastatic prostate cancer, such as androgen receptor pathway inhibitors, taxane-based chemotherapy, radiopharmaceuticals, and immunotherapy. However, prostate cancer remains the leading cause of cancer deaths in nonsmoking men. Fortunately, many more novel agents are under investigation.

Areas covered

We provide an overview of the broad group of novel therapies for metastatic prostate cancer, with an emphasis on active and recruiting clinical trials that have been recently published and/or presented at national or international meetings.

Expert opinion

The future for patients with metastatic prostate cancer is promising, with further development of novel therapies such as radiopharmaceuticals. Based on a growing understanding of prostate cancer biology, novel agents are being designed to overcome resistance to approved therapies. There are many trials using novel agents either as monotherapy or in combination with already approved agents with potential to further improve outcomes for men with advanced prostate cancer.

KEYWORDS:

• Prostate cancer
• next generation androgen receptor pathway inhibitor
• targeted therapy
• radiopharmaceutical
• immunotherapy

Declaration of interest

PC Barata has received personal fees from BMS, Merck, and EMD Serono, grants from Roche, personal fees from Eisai, Exelixis, Pfizer, Caris Life Sciences, Myovant, and UroToday, and nonfinancial support from Guardant360. AY Jia has served on the advisory board for Myovant. JA Garcia received personal fees from Pfizer, Aptitude Health, and the US Food and Drug Administration. OY Mian has received research funding from Gilead, Varian, and PathomIQ, has served as a consultant for Bayer, has served as an advisory board member for Blue Earth Diagnostics, and has received travel honoraria from NCCN, ASTRO, and ASCO.

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosure

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This paper was not funded.